Veeda Lifesciences Partners with Mango Sciences for AI in Trials
Veeda Lifesciences Partners with Mango Sciences for AI in Trials
Veeda Lifesciences, a global contract research organization (CRO), has announced a significant partnership with Mango Sciences, a Boston-based healthcare AI and data company. This collaboration aims to leverage cutting-edge technology to transform the clinical trial landscape. Veeda seeks to enhance the efficiency and quality of its Clinical Trials services through AI innovations, a move that positions it as a leader in the evolving field of healthcare.
Utilizing AI for Improved Clinical Trials
With the investment in Mango Sciences, Veeda plans to integrate the AI-powered Querent™ platform into its operations. This integration is designed to speed up patient identification processes, ensuring they are comprehensive and inclusive. The introduction of these capabilities will allow for more effective recruitment and a broader range of patient demographics, ultimately reflecting a global standard in clinical research.
Dr. Mahesh Bhalgat's Vision for Oncology Development
Dr. Mahesh Bhalgat, the Group CEO and Managing Director of Veeda Clinical Research Limited, has expressed excitement about the potential this partnership brings to oncology drug development. "Our partnership will transform Veeda into an AI-driven organization, addressing the pressing need for diversity in clinical trials—a necessity for regulators and pharmaceutical companies alike," he stated. This innovative approach aligns with Veeda's vision to leverage technology in meeting contemporary challenges in drug development.
Advancing Technology and Operational Efficiency
The partnership with Mango Sciences is a strategic move that underlines Veeda's commitment to modernization and digital transformation in its clinical operations. By utilizing advanced AI analytics, Veeda aims to streamline processes, improve patient matching, and ensure high-quality standards throughout its clinical trials. This endeavor will not only reduce costs but also optimize timelines for bringing new therapies to market.
Innovative Technological Integrations
Dr. Mohit Misra, Founder & CEO of Mango Sciences, emphasized the integration of Large Language Models (LLMs) and Generative-AI into Querent™. This innovative technology aims to improve operational efficiencies and enhance the use of real-world evidence. As a result, the partnership is geared towards identifying the best drug options for patients, showcasing a patient-centric approach to drug development.
Strengthening Access to Diverse Patient Cohorts
With previous investments and acquisitions, Veeda has solidified its standing as a tech-enabled CRO. The acquisition of Health Data Specialists has granted Veeda exclusive access to oncology patient pools in key regions, further supporting its mission to enhance clinical trial diversity. This strategic positioning allows Veeda to maintain a competitive advantage while delivering exceptional services to biopharmaceutical customers on a global scale.
About Veeda Lifesciences
Veeda Lifesciences (Veeda Clinical Research Limited) provides a comprehensive portfolio of services throughout various stages of the drug development lifecycle. By supporting biotech and pharmaceutical companies, Veeda offers capabilities that range from non-clinical and pre-clinical development to clinical pharmacology and trials.
About Mango Sciences
Mango Sciences is dedicated to transforming healthcare through advanced data analytics. Founded by seasoned professionals in healthcare and life sciences, Mango Sciences is committed to improving patient care and representation in clinical research.
Frequently Asked Questions
What is the focus of the partnership between Veeda and Mango Sciences?
The partnership aims to integrate AI technologies to enhance clinical trial processes, improving efficiency and data management.
How does the Querent™ platform benefit Veeda's operations?
Querent™ streamlines patient identification, allowing for more comprehensive and diverse recruitment for clinical trials.
Why is diversity important in clinical trials?
Diversity in clinical trials ensures that research findings are applicable to a wider population, meeting regulatory expectations and improving patient care.
What is Veeda's strategy for modernization?
Veeda is investing in technology and digital solutions to enhance operational efficiency and quality assurance in its clinical research activities.
Who are the key figures in this partnership?
Dr. Mahesh Bhalgat from Veeda and Dr. Mohit Misra from Mango Sciences are pivotal in driving the vision for this partnership.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
